Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$11.82 USD
+0.05 (0.42%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $11.85 +0.03 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Lexeo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 121 | 77 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 3 | 3 | NA | NA | NA |
Total Current Assets | 124 | 80 | NA | NA | NA |
Net Property & Equipment | 1 | 1 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 3 | 3 | NA | NA | NA |
Total Assets | 140 | 97 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 4 | 3 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 1 | 1 | NA | NA | NA |
Accrued Expenses | 11 | 8 | NA | NA | NA |
Income Taxes Payable | 0 | 1 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 17 | 14 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 1 | 2 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 185 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 26 | 210 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 295 | 2 | NA | NA | NA |
Retained Earnings | -182 | -115 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | 114 | -113 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 140 | 97 | NA | NA | NA |
Total Common Equity | 114 | -113 | 0 | 0 | 0 |
Shares Outstanding | 26.60 | NA | NA | NA | NA |
Book Value Per Share | 4.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Lexeo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 195 | 121 | 35 | -99,999 |
Receivables | NA | 0 | 0 | 0 | NA |
Notes Receivable | NA | 0 | 0 | 0 | NA |
Inventories | NA | 0 | 0 | 0 | NA |
Other Current Assets | NA | 3 | 3 | 3 | NA |
Total Current Assets | NA | 198 | 124 | 39 | NA |
Net Property & Equipment | NA | 1 | 1 | 1 | NA |
Investments & Advances | NA | 0 | 0 | 0 | NA |
Other Non-Current Assets | NA | 0 | 0 | 0 | NA |
Deferred Charges | NA | 0 | 0 | 0 | NA |
Intangibles | NA | 0 | 0 | 0 | NA |
Deposits & Other Assets | NA | 3 | 3 | 3 | NA |
Total Assets | NA | 213 | 140 | 55 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | NA |
Accounts Payable | NA | 4 | 4 | 3 | NA |
Current Portion Long-Term Debt | NA | 0 | 0 | 4 | NA |
Current Portion Capital Leases | NA | 1 | 1 | 1 | NA |
Accrued Expenses | NA | 15 | 11 | 14 | NA |
Income Taxes Payable | NA | 0 | 0 | 0 | NA |
Other Current Liabilities | NA | 0 | 0 | 0 | NA |
Total Current Liabilities | NA | 22 | 17 | 23 | NA |
Mortgages | NA | 0 | 0 | 0 | NA |
Deferred Taxes/Income | NA | 0 | 0 | 0 | NA |
Convertible Debt | NA | 0 | 0 | 0 | NA |
Long-Term Debt | NA | 0 | 0 | 0 | NA |
Non-Current Capital Leases | NA | 1 | 1 | 1 | NA |
Other Non-Current Liabilities | NA | 0 | 185 | NA | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | NA |
Total Liabilities | NA | 30 | 26 | 218 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | NA |
Common Stock (Par) | NA | 0 | 0 | 0 | NA |
Capital Surplus | NA | 386 | 295 | 5 | NA |
Retained Earnings | NA | -204 | -182 | -168 | NA |
Other Equity | NA | 0 | 0 | 0 | NA |
Treasury Stock | NA | 0 | 0 | 0 | NA |
Total Shareholder's Equity | NA | 183 | 114 | -163 | NA |
Total Liabilities & Shareholder's Equity | NA | 213 | 140 | 55 | NA |
Total Common Equity | 0 | 183 | 114 | -163 | 0 |
Shares Outstanding | 32.90 | 32.90 | 26.60 | NA | NA |
Book Value Per Share | 0.00 | 5.56 | 4.27 | 0.00 | 0.00 |